Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
NASA’s history-making moon mission aims to send the first woman and person of color to deep space - 2Ministry: New German petrol price regulation takes effect on April 1
- 3Clones of Stumpy, Washington D.C.'s beloved cherry blossom tree, have flowered for the first time
- 4Book excerpt: "Enough" by Dr. Ania Jastreboff and Oprah Winfrey
- 5Ski Resorts Universally: A Colder time of year Wonderland Guide
- Bestselling author Colleen Hoover reveals cancer journey
- Dominating Your Cash: The Fundamental Manual for Overseeing Individual accounting records
- Forget 'Outer Banks.' These Gen Z-ers just want to watch 'M*A*S*H*' and 'Gilmore Girls.'
- We may be witnessing the messy death of a star in real time
- Uzbekistan launches €9.46 billion green energy push, covering nation’s power needs
- New peace laureate: Iran's arrest of Mohammadi 'confession of fear'
- Apollo's impatient old-timers are rooting for NASA's return to the moon with Artemis II launch
- The 10 Most Famous Works of art Ever
- Family-Accommodating Snow Sports Experiences
